Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma
- 7 November 2008
- journal article
- Published by Springer Nature in International Journal of Hematology
- Vol. 88 (4) , 396-402
Abstract
Bortezomib blocks the activation of nuclear factor-κB-mediated pro-inflammatory cytokines, however, systemic inflammatory symptoms following bortezomib administration have been reported, although their mechanisms remain elusive. Serum samples were obtained from five patients, who participated in a phase I/II study of Japanese patients with relapsed or refractory multiple myeloma (MM), and developed cyclic fever following bortezomib administration, to measure cytokine levels. Significant correlations between interleukin (IL)-6 or interferon (IFN)-γ and the body temperature were observed in two patients each. Furthermore, we found that IL-6 elevation was not observed after the addition of bortezomib to any examined MM cells alone, but was noted in a case of bone marrow stromal cells (BMSCs) of macrophage origin alone or co-cultured with MM cells. Similarly, a marked increase in IFN-γ levels was induced by adding bortezomib to BMSCs of fibroblast origin. Although this investigation was a preliminary study with a small number of patients, our results suggested that pro-inflammatory cytokines causing bortezomib-associated fever were secreted from BMSCs rather than MM cells.Keywords
This publication has 18 references indexed in Scilit:
- Effects of bortezomib on pro‐inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman DiseaseBritish Journal of Haematology, 2006
- Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myelomaBlood, 2006
- KEY INFLAMMATORY SIGNALING PATHWAYS ARE REGULATED BY THE PROTEASOMEShock, 2006
- Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro‐inflammatory cytokinesEuropean Journal of Haematology, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaBritish Journal of Haematology, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Establishment of a variety of human bone marrow stromal cell lines by the recombinant SV40‐adenovirus vectorJournal of Cellular Physiology, 1991